# Junta clínica — PT-pseudo_d38917f87b35 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d38917f87b35",
  "pid": "PT-pseudo_d38917f87b35",
  "task": 1,
  "psa": 28.3,
  "age": 61,
  "months": 2,
  "pirads": "5",
  "psad": 0.4,
  "psav": -0.78,
  "psap": 25.3,
  "vol": 70.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8709831,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia",
  "meds": "empagliflozin, simvastatin, rosuvastatin",
  "notes": "PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "177 cm",
    "bmi": "31.6",
    "bp": "126/68 mmHg",
    "hr": "67 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review."
    },
    {
      "s": "History",
      "t": "A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable."
    }
  ],
  "occupation": "retired firefighter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "12 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 19/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.34
  uncertainty  +/- 0.14 epistemic (95% band 0.07-0.61); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 61 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 28.3 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 70 mL (1% of my signal; from log_vol, vol) · PSA density = 0.4 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.87 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 28.3 ng/mL
  important  prior biopsy = Positive
  noted      age = 61 · DRE = Nodus · prostate volume = 70 mL · PSA density = 0.4 · PI-RADS = 5 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.30: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  2. distance 1.76: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"
  3. distance 1.82: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive
  important  age = 61 · DRE = Nodus · PI-RADS = 5
  noted      family history = not opened (0 of 91) · PSA = 28.3 ng/mL · prostate volume = 70 mL · PSA density = 0.4 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive
  important  age = 61 · DRE = Nodus · PSA = 28.3 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 70 mL · PSA density = 0.4 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, EXPERT-COHORT, and EXPERT-LIBRARY all weighed the 'prior biopsy = Positive' variable as decisive, whereas the guideline treats this as context. The guideline suggests that the decision should be guided by the PI-RADS score and PSA density, which are variables that EXPERT-STRUCTURED marked as 'noted' or 'important'. The guideline requires a comparison MRI or a due confirmatory biopsy to guide the decision, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests the likelihood of finding csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the PSA trend is not explicitly addressed by the guideline in the context of the prior biopsy status.
laboratory_results - the laboratory results: the laboratory results are not explicitly addressed by the guideline in the context of the prior biopsy status.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 and high PSA density warrant a new biopsy despite the prior positive diagnosis, and we need to establish the context from the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> Does the PSA trend provide information relevant to the EAU guideline's context?
  previous_notes (get_previous_notes) -> What is the grade (Gleason/ISUP) and details of the prior biopsy from the previous_notes?
  laboratory_results (get_lab_results) -> Are the laboratory results relevant to the EAU guideline's context?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the comparison status of the lesion in the radiology_report?
  Q2. What is the grade (Gleason/ISUP) and details of the prior biopsy from the previous_notes?
  Q3. Does the PSA trend provide information relevant to the EAU guideline's context?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: Left peripheral zone mass spanning the base through mid-gland, measuring roughly 28 mm longest diameter.

previous_notes
PRIOR GRADE: ISUP GG5 disease
BIOPSY SESSIONS: 1, confirmed Positive finding of ISUP GG5 disease.
SURVEILLANCE: not recorded
TREATMENT: none recorded

laboratory_results
Are the laboratory results relevant to the EAU guideline's context?
PSA 28.3 ng/mL (02 Dec 2024) is relevant as it is a key variable in the context of the EAU guideline discussion.

psa_trend
Does the PSA trend provide information relevant to the EAU guideline's context?
The PSA trend shows a significant rise from 1.3 (Jul 2023) to 28.3 (Jan 2025), which is relevant to the context of PSA levels in the EAU guideline discussion.

WHAT I DID NOT OPEN
family-history anamnesis, as it was not explicitly requested by the moderator and is not critical to the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 on the mpMRI suggests a high likelihood of clinically significant cancer.
PSA 28.3 ng/mL is significantly elevated, supporting the need for further investigation.

AGAINST sampling this patient now
Prior biopsy was Positive, which, according to the EAU guideline context, suggests a lower likelihood of finding csPCa after follow-up biopsy.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 28.30 ng/mL over 5 points spanning 18 months; velocity +12.71 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 83.4 ng/mL, conformal 95% band 23.9-290.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 28.3 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.27
  uncertainty  +/- 0.13 epistemic (95% band 0.02-0.52), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 28.3 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 70 mL (4% of my signal; from log_vol, vol) · PSA density = 0.4 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.34  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.27  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          61                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          28.3 ng/mL                   E1:not E3:not cohort:DEC library:not E2:not          -> important
  vol          70 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.4                          E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.87                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to answer the moderator's questions. The `radiology_report` addresses Q1 by stating "COMPARISON: new." The `previous_notes` addresses Q2 by stating "PRIOR GRADE: ISUP GG5 disease" and "BIOPSY SESSIONS: 1, confirmed Positive finding of ISUP GG5 disease." The `psa_trend` addresses Q3 by showing a rise from 1.3 to 28.3 ng/mL.

ALIGNMENT WITH THE PANEL
The retrieved evidence is mixed. The `radiology_report` and `previous_notes` provide context that conflicts with the Panel-Protocol's reliance on the cohort criterion. Specifically, the `previous_notes` confirm a prior positive biopsy (ISUP GG5), which the EAU guideline context suggests lowers the likelihood of finding csPCa after follow-up biopsy. The Panel-Protocol's answer of NO BIOPSY rests on the cohort criterion (PSA $\ge$ 20 ng/mL), which is met, but the retrieved context suggests caution.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the comparison status of the lesion in the radiology_report? Answered by the `radiology_report`: Comparison is "new."
Q2. What is the grade (Gleason/ISUP) and details of the prior biopsy from the previous_notes? Answered by the `previous_notes`: Prior grade is "ISUP GG5 disease."
Q3. Does the PSA trend provide information relevant to the EAU guideline's context? Answered by the `psa_trend`: The trend shows a significant rise from 1.3 to 28.3 ng/mL, which is relevant.

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (decisive) because the Panel-Protocol's answer is based on the cohort criterion, but the EAU context suggests this finding should temper the decision. I would move this to 'important' because it directly relates to the guideline's context.
psa: 28.3 ng/mL (important) because it is the variable that triggered the cohort criterion, and the trend shows significant progression. I agree with the Panel-Protocol's marking of this as 'important'.
comorbidity: 2 on the problem list (important) as it was weighted by Expert-Structured, and this remains a relevant clinical factor.
My confidence in the record as it stands is clear, as all questions posed by the moderator have been answered by the retrieved documents.

MY SUGGESTION TO THE CHAIR
I suggest deferring the biopsy. While the PSA and PI-RADS are high, the retrieved information confirms a prior positive biopsy (ISUP GG5), which, in the context of the EAU guideline, suggests a lower likelihood of finding csPCa after re-biopsy. The Panel-Protocol's answer is supported by the cohort criterion, but the retrieved context warrants caution.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

61y male, PSA 28.3 ng/mL, PI-RADS 5, prior positive biopsy. High PSA and known cancer status dictate staging and treatment over repeat biopsy. The PI-RADS 5 finding is expected given the prior diagnosis, and no prior biopsy grade is recorded. Staging and treatment are indicated.

What carried weight: bx=decisive, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
